Hyloris Pharmaceuticals SA (HYL.BR)

12.5 €

+0.20 (+1.63%)
Symbol HYL.BR
Price 12.5 €
Beta 0.651
Volume Avg. 0.01M
Market Cap 350.005M
Shares () -
52 Week Range 10.8-14.76
1y Target Est -
DCF Unlevered HYL.BR DCF ->
DCF Levered HYL.BR LDCF ->
ROE -20.89% Sell
ROA -17.41% Sell
Operating Margin -
Debt / Equity 1.61% Neutral
P/E -27.17 Strong Sell
P/B 6.18 Strong Buy


Consensus EPS

Upgrades & Downgrades

Mr. Stijn Van Rompay

Hyloris Pharmaceuticals SA engages in the develop, manufacture, and deliver pharmaceutical products to address unmet medical needs in cardiovascular health, oncology, women's health, and other major therapeutic areas. The company offers cardiovascular products for atrial fibrillation, acute coronary syndrome, advanced heart failure, congestive heart failure, acute coronary syndrome, and coronary heart disease. It also provides other products, such as post operation pain, dental indications, severe and recurring vulvovaginal candidiasis, acute myeloid leukemia and small cell lung cancer, IC/PBS, attention deficit hyperactivity disorder, and viral infection. Hyloris Pharmaceuticals SA was incorporated in 2012 and is headquartered in Liège, Belgium.